Mágnesesrezonancia-képalkotás alemtuzumab- és teriflunomidkezelés során
Our work aimed to review the published results of magnetic resonance imaging (MRI) obtained in the course of alemtuzumab and teriflunomide therapy in multiplex sclerosis. In multiplex sclerosis MRI sensitively detects subclinical pathological processes, which do not manifest clinically in the early...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
LifeTime Media Kft
2017
|
| Sorozat: | IDEGGYOGYASZATI SZEMLE / CLINICAL NEUROSCIENCE
70 No. 1-2 |
| doi: | 10.18071/isz.70.0015 |
| mtmt: | 3202615 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/11668 |
| Tartalmi kivonat: | Our work aimed to review the published results of magnetic resonance imaging (MRI) obtained in the course of alemtuzumab and teriflunomide therapy in multiplex sclerosis. In multiplex sclerosis MRI sensitively detects subclinical pathological processes, which do not manifest clinically in the early course of the disease, however have substantial significance from the viewpoint of the long-term disease prognosis. MRI has an increasingly important role in the early monitoring of the therapeutic efficacy. In the last 15 years several clinical trials have been conducted with alemtuzumab and teriflunomide in multiple sclerosis providing evidence about the favourable clinical effect of these drugs. MRI images were acquired in these trials as well, and the results published recently in the scientific literature. These MRI results denote the suppression of the disease activity and the neurodegenerative processes, which may imply a favourable effect on the long-term prognosis of the disease. |
|---|---|
| Terjedelem/Fizikai jellemzők: | 15-24 |
| ISSN: | 0019-1442 |